Devices for remote monitoring of Parkinson’s disease (HTG657)Product type:GuidanceProgramme:HealthTech guidanceLast updated: 25 January 2024Published: 25 January 2023
Foslevodopa–foscarbidopa for treating advanced Parkinson’s with motor symptoms (TA934)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 November 2023
Suspected neurological conditions: recognition and referral (NG127)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 1 May 2019
Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea (TA605)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 October 2019
Parkinson’s disease in adults (NG71)Product type:GuidanceProgramme:NICE guidelinePublished: 19 July 2017
Path Finder for freezing of gait in people with Parkinson’s disease (MIB170)Product type:AdviceProgramme:Medtech innovation briefingPublished: 25 January 2019
Severe sialorrhoea (drooling) in children and young people with chronic neurological disorders: oral glycopyrronium bromide (ES5)Product type:AdviceProgramme:Evidence summaryPublished: 14 February 2017
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)Product type:AdviceProgramme:Evidence summaryPublished: 15 December 2015
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)Product type:AdviceProgramme:Evidence summaryPublished: 6 October 2015
Postural hypotension in adults: fludrocortisone (ESUOM20)Product type:AdviceProgramme:Evidence summaryPublished: 1 October 2013
Suspected neurological conditions: recognition and referral (QS198)Product type:Quality standardPublished: 8 January 2021
Gosuranemab for treating progressive supranuclear palsy [ID1607]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Levodopa, carbidopa monohydrate and entacapone intestinal gel for treating the symptoms of advanced Parkinson’s disease [ID4005]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Extradural motor cortex stimulation (EMCS) for Parkinson's diseaseStatus:Topic prioritisationProgramme:Interventional procedures guidanceExpected publication date: TBC
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease TS ID 11941Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Deutetrabenazine for treating tardive dyskinesia [ID6550]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Levodopa inhaled for patients with Parkinson’s disease who experience ‘off’ episodes (motor response fluctuations) [TSID8778]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremorStatus:In development | In consultationProgramme:Interventional procedures guidanceConsultation end date: 11 February 2026Expected publication date: TBC